Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development
dc.contributor.author | Sanda, Martin G. | en_US |
dc.contributor.author | Charles, Linda G. | en_US |
dc.contributor.author | Xie, Yilin C. | en_US |
dc.contributor.author | Roessler, Blake J. | en_US |
dc.contributor.author | Restifo, Nicholas P. | en_US |
dc.date.accessioned | 2006-09-08T20:02:35Z | |
dc.date.available | 2006-09-08T20:02:35Z | |
dc.date.issued | 2000-04 | en_US |
dc.identifier.citation | Charles, Linda G.; Xie, Yilin C.; Restifo, Nicholas P.; Roessler, Blake; Sanda, Martin G.; (2000). "Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development." World Journal of Urology 18(2): 136-142. <http://hdl.handle.net/2027.42/42168> | en_US |
dc.identifier.issn | 0724-4983 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/42168 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=10854149&dopt=citation | en_US |
dc.description.abstract | One potential use for prostate-cancer-associated genes discovered through ongoing genetics studies entails the construction of virus- or plasmid-based recombinant vector vaccines encoding these new tumor-associated antigens (TAA) to induce TAA-specific immune responses for the prevention or therapy of prostate cancer. Clinical trials evaluating prototypes of such recombinant vaccines are under way. TAA-encoding recombinant vector vaccines, however, have not previously been evaluated in a prostate-cancer animal model. For assessment of the potential susceptibility of prostate cancer to genetic immunization strategies using TAA-encoding recombinant vectors, the antitumor efficacy of a model recombinant viral vector encoding a TAA was evaluated in rat Dunning prostate cancer. Recombinant vaccinia was chosen as a prototype virus vector encoding a TAA for these studies, and β-galactosidase was chosen as a model target TAA. Dunning AT-2 cells were transduced with a retroviral vector to express β-galactosidase, and the susceptibility of tumorigenic AT-2-lacZ cells to immunization with vaccinia-lacZ was measured using protection studies in Copenhagen and nu/nu rats. Stably transduced AT-2-lacZ cells expressing β-galactosidase as measured by enzymatic substrate-based assays were found to retain their tumorigenicity in vivo despite abundant expression of rat major histocompatibility complex (MHC) class I. Immunization with model TAA-encoding recombinant vaccinia-lacZ conferred significant protection against subsequent growth of AT-2-lacZ cells in vivo ( P =0.01); however, the efficacy of such immunization was markedly dependent on the volume of tumor challenge. The antitumor efficacy of TAA-encoding recombinant vaccinia immunization was abrogated in nu/nu rats, suggesting a T-cell-dependent mechanism of activity. These studies suggest that prostate cancer may be a suitable target for immunization strategies using TAA-encoding recombinant vectors. Such immunization strategies may be more effective in settings of minimal cancer burden. | en_US |
dc.format.extent | 129616 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag; Springer-Verlag Berlin Heidelberg | en_US |
dc.subject.other | Legacy | en_US |
dc.title | Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Medicine/Rheumatology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA, US | en_US |
dc.contributor.affiliationum | Department of Surgery/Urology, University of Michigan School of Medicine, 2916 Taubman Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0330, USA e-mail: msanda@umich.edu, Tel.: +1-734-6475644, Fax: +1-734-6479271, US | en_US |
dc.contributor.affiliationum | Department of Surgery/Urology, University of Michigan School of Medicine, 2916 Taubman Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0330, USA e-mail: msanda@umich.edu, Tel.: +1-734-6475644, Fax: +1-734-6479271, US | en_US |
dc.contributor.affiliationum | Department of Surgery/Urology, University of Michigan School of Medicine, 2916 Taubman Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0330, USA e-mail: msanda@umich.edu, Tel.: +1-734-6475644, Fax: +1-734-6479271, US | en_US |
dc.contributor.affiliationother | Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA, US | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 10854149 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/42168/1/345-18-2-136_00180136.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/s003450050186 | en_US |
dc.identifier.source | World Journal of Urology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.